{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:26:49Z","timestamp":1793406409910,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s41669-025-00594-y","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T08:53:47Z","timestamp":1758185627000},"page":"997-1008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Budget Impact Model of Treatment of Primary Immune Deficiency with Immune Globulin Subcutaneous (Human), 20% (IgPro20) (Hizentra)"],"prefix":"10.1007","volume":"9","author":[{"given":"Rajiv","family":"Mallick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashad","family":"Carlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"issue":"1","key":"594_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","volume":"40","author":"SG Tangye","year":"2020","unstructured":"Tangye SG, Al-herz W, Bousfiha A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies expert committee. J Clin Immunol. 2020;40(1):24\u201364.","journal-title":"J Clin Immunol"},{"issue":"1","key":"594_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10875-017-0464-9","volume":"38","author":"C Picard","year":"2018","unstructured":"Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38(1):96\u2013128. https:\/\/doi.org\/10.1007\/s10875-017-0464-9.","journal-title":"J Clin Immunol"},{"issue":"1","key":"594_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4065\/84.1.16","volume":"84","author":"AY Joshi","year":"2009","unstructured":"Joshi AY, Iyer VN, Hagan JB, St Sauver JL, Boyce TG. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc. 2009;84(1):16\u201322.","journal-title":"Mayo Clin Proc"},{"key":"594_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10875-007-9103-1","volume":"27","author":"JM Boyle","year":"2007","unstructured":"Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency disease in the United States. J Clin Immunol. 2007;27:497\u2013502.","journal-title":"J Clin Immunol"},{"key":"594_CR5","unstructured":"Centers for Disease Control and Prevention (CDC). Primary immunodeficiency (PI). https:\/\/www.cdc.gov\/genomics\/disease\/primary_immunodeficiency.htm. Accessed 12 Oct 2023."},{"issue":"2","key":"594_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/cei.12485","volume":"179","author":"S Jolles","year":"2015","unstructured":"Jolles S, Orange J, Gardulf A, Stein M, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179(2):146\u201360.","journal-title":"Clin Exp Immunol"},{"issue":"Suppl 3","key":"594_CR7","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1111\/trf.15020","volume":"58","author":"Y Gernez","year":"2018","unstructured":"Gernez Y, Baker MG, Maglione PJ. Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy. Transfusion. 2018;58(Suppl 3):3056\u201364.","journal-title":"Transfusion"},{"issue":"2","key":"594_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1023\/A:1006678312925","volume":"20","author":"HM Chapel","year":"2000","unstructured":"Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94\u2013100.","journal-title":"J Clin Immunol"},{"issue":"Suppl 1","key":"594_CR9","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.tmrv.2009.09.011","volume":"24","author":"N Shehata","year":"2010","unstructured":"Shehata N, Palda V, Bowen T, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev. 2010;24(Suppl 1):S28-50.","journal-title":"Transfus Med Rev"},{"issue":"Suppl 2","key":"594_CR10","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1007\/s10875-012-9853-2","volume":"33","author":"RS Shapiro","year":"2013","unstructured":"Shapiro RS. Why I use subcutaneous immunoglobulin (SCIG). J Clin Immunol. 2013;33(Suppl 2):S95\u20138.","journal-title":"J Clin Immunol"},{"issue":"4","key":"594_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.iac.2008.07.002","volume":"28","author":"M Berger","year":"2008","unstructured":"Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin N Am. 2008;28(4):779\u2013802, viii. https:\/\/doi.org\/10.1016\/j.iac.2008.07.002.","journal-title":"Immunol Allergy Clin N Am."},{"issue":"4","key":"594_CR12","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","volume":"114","author":"A Gardulf","year":"2004","unstructured":"Gardulf A, Nicolay U, Math D, Asensio O, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114(4):936\u201342.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"594_CR13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s10875-006-9031-5","volume":"26","author":"JM Kittner","year":"2006","unstructured":"Kittner JM, Grimbacher B, Wulff W, J\u00e4ger B, Schmidt RE. Patients\u2019 attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol. 2006;26(4):400\u20135.","journal-title":"J Clin Immunol"},{"issue":"1","key":"594_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","volume":"26","author":"U Nicolay","year":"2006","unstructured":"Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26(1):65\u201372.","journal-title":"J Clin Immunol"},{"issue":"8","key":"594_CR15","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s10875-018-0562-3","volume":"38","author":"R Mallick","year":"2018","unstructured":"Mallick R, Jolles S, Kanegane H, Agbor-Tarh D, Rojavin M. Treatment satisfaction with subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency: a pooled analysis of six Hizentra\u00ae studies. J Clin Immunol. 2018;38(8):886\u201397.","journal-title":"J Clin Immunol"},{"key":"594_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2147\/BTT.S25188","volume":"6","author":"L Kobrynski","year":"2012","unstructured":"Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277\u201387. https:\/\/doi.org\/10.2147\/BTT.S25188.","journal-title":"Biologics"},{"issue":"1","key":"594_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12865-020-00371-y","volume":"21","author":"R Mallick","year":"2020","unstructured":"Mallick R, Henderson T, Lahue BJ, Kafal A, Bassett P, Scalchunes C. Subcutaneous immunoglobulin in primary immunodeficiency\u2014impact of training and infusion characteristics on patient-reported outcomes. BMC Immunol. 2020;21(1):47.","journal-title":"BMC Immunol"},{"issue":"1","key":"594_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-3148.2012.01201.x","volume":"23","author":"A Martin","year":"2012","unstructured":"Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2012;23(1):55\u201360. https:\/\/doi.org\/10.1111\/j.1365-3148.2012.01201.x.","journal-title":"Transfus Med"},{"key":"594_CR19","unstructured":"Immune Deficiency Foundation. Patient reported outcomes and treatment survey. 2017. https:\/\/www.census.gov\/library\/publications\/2011\/dec\/c2010br-03.html. Accessed 12 Oct 2023."},{"key":"594_CR20","unstructured":"Immune Deficiency Foundation. 2018 national treatment survey. https:\/\/primaryimmune.org\/sites\/default\/files\/IDF-2018-Treatment-Survey.pdf. Accessed 12 Oct 2023."},{"issue":"2","key":"594_CR21","first-page":"e41","volume":"6","author":"R Luthra","year":"2014","unstructured":"Luthra R, Quimbo R, Iyer R, Luo M. An analysis of intravenous immunoglobin site of care: home versus outpatient hospital. Am J Pharm Benefits. 2014;6(2):e41\u20139.","journal-title":"Am J Pharm Benefits."},{"issue":"2","key":"594_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s41669-023-00386-2","volume":"7","author":"R Mallick","year":"2023","unstructured":"Mallick R, Carlton R, Van Stiphout J. A budget impact model of maintenance treatment of chronic inflammatory demyelinating polyneuropathy with IgPro20 (Hizentra) relative to intravenous immunoglobulins in the United States. Pharmacoecon Open. 2023;7(2):243\u201355. https:\/\/doi.org\/10.1007\/s41669-023-00386-2.","journal-title":"Pharmacoecon Open."},{"issue":"2","key":"594_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1017\/S0266462300006942","volume":"11","author":"A Gardulf","year":"1995","unstructured":"Gardulf A, Jonsson G. A comparison of the patient-borne costs of therapy with gamma globulin given at the hospital or at home. Int J Technol Assess Health Care. 1995;11(2):345\u201353.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"594_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10198-004-0250-5","volume":"6","author":"B H\u00f6gy","year":"2005","unstructured":"H\u00f6gy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance [published correction appears in Eur J Health Econ. 2005 Sep;6(3):243] [published correction appears in Eur J Health Econ. 2008 May;9(2):203]. Eur J Health Econ. 2005;6(1):24\u20139.","journal-title":"Eur J Health Econ"},{"key":"594_CR25","unstructured":"Liu Z, Albon E, Hyde C. The effectiveness and cost effectiveness of immunoglobulin replacement therapy for primary immunodeficiency and chronic lymphocytic leukaemia: a systematic review and economic evaluation. University of Birmingham. 2005. https:\/\/www.birmingham.ac.uk\/Documents\/college-mds\/haps\/projects\/WMHTAC\/REPreports\/2005\/IgRT.pdf. Accessed 12 Oct 2023."},{"issue":"2","key":"594_CR26","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2249.2009.04079.x","volume":"160","author":"J Beaut\u00e9","year":"2010","unstructured":"Beaut\u00e9 J, Levy P, Millet V, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol. 2010;160(2):240\u20135.","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"594_CR27","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/17425247.2018.1546692","volume":"15","author":"A Kafal","year":"2018","unstructured":"Kafal A, Vinh D, Langelier M. Prefilled syringes for immunoglobulin G (IgG) replacement therapy: clinical experience from other disease settings. Expert Opin Drug Deliv. 2018;15(12):1199\u2013209.","journal-title":"Expert Opin Drug Deliv"},{"key":"594_CR28","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2147\/PPA.S154181","volume":"12","author":"S Vermeire","year":"2018","unstructured":"Vermeire S, D\u2019Heygere F, Nakad A, et al. Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study. Patient Prefer Adherence. 2018;12:1193\u2013202. https:\/\/doi.org\/10.2147\/PPA.S154181.","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"594_CR29","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1517\/17425247.2014.923400","volume":"11","author":"RG Ingle","year":"2014","unstructured":"Ingle RG, Agarwal AS. Pre-filled syringe\u2014a ready-to-use drug delivery system: a review. Expert Opin Drug Deliv. 2014;11(9):1391\u20139.","journal-title":"Expert Opin Drug Deliv"},{"key":"594_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2012.01201.x","author":"J Jezek","year":"2013","unstructured":"Jezek J, Darton NJ, Derham BK, Royle N, Simpson I. Biopharmaceutical formulations for pre-filled delivery devices. Expert Opin Drug Deliv. 2013. https:\/\/doi.org\/10.1111\/j.1365-3148.2012.01201.x.","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"594_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1365-3148.2012.01201.x","volume":"1","author":"S Makwana","year":"2011","unstructured":"Makwana S, Basu B, Makasana Y, Dharamsi A. Prefilled syringes: an innovation in parenteral packaging. Int J Pharm Investig. 2011;1(4):200\u20136. https:\/\/doi.org\/10.1111\/j.1365-3148.2012.01201.x.","journal-title":"Int J Pharm Investig."},{"key":"594_CR32","unstructured":"Academy of Managed Care Pharmacy. The AMCP Format for Formulary Submissions 5.0. April 2024. https:\/\/www.amcp.org\/sites\/default\/files\/2024-04\/AMCP-Format-5.0-JMCP-web_0.pdf"},{"issue":"1","key":"594_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis\u2014principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health."},{"key":"594_CR34","unstructured":"Centers for Medicare and Medicaid Services (CMS). 2023 ASP Pricing File. July 2023 Pricing File. Effective July 1, 2023 through September 30, 2023. https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2023-asp-drug-pricing-files. Accessed 19 Jun 2023."},{"key":"594_CR35","unstructured":"Red Book Online. IBM Micromedex. 2022. https:\/\/www.ibm.com\/products\/micromedex-red-book. Accessed 20 Jul 2023."},{"key":"594_CR36","unstructured":"AMCP Pharmaceutical Payment Methods, 2013 Update. https:\/\/www.amcp.org\/guide-pharmaceutical-payment-methods. Accessed 28 Nov 2022."},{"key":"594_CR37","first-page":"1","volume":"36","author":"CD Fryar","year":"2021","unstructured":"Fryar CD, Carroll MD, Gu Q, Afful J, Ogden CL, National Center for Health Statistics. Anthropometric reference data for children and adults: United States, 2015\u20132018. Vital Health Stat. 2021;36:1\u201344.","journal-title":"Vital Health Stat"},{"key":"594_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12865-024-00608-0","volume":"25","author":"R Mallick","year":"2024","unstructured":"Mallick R, Solomon G, Bassett P, et al. Subcutaneous immunoglobulin replacement therapy in patients with immunodeficiencies\u2014impact of drug packaging and administration method on patient-reported outcomes. BMC Immunol. 2024;25:18.","journal-title":"BMC Immunol"},{"issue":"1","key":"594_CR39","first-page":"24","volume":"5","author":"B Slen","year":"2014","unstructured":"Slen B. Infused therapies: cost savings benefits through home infusion. Pharm Times. 2014;5(1):24\u20135.","journal-title":"Pharm Times"},{"key":"594_CR40","unstructured":"Centers for Medicare & Medicaid Services. Updated Interim Report to Congress. Evaluation of the Medicare Patient Intravenous Immunoglobulin Demonstration Project. https:\/\/www.cms.gov\/priorities\/innovation\/data-and-reports\/2022\/ivig-updatedintrtc. Accessed 5 Jan 2025."},{"key":"594_CR41","unstructured":"United States Bureau of Labor Statistics. Consumer price index (CPI). https:\/\/www.bls.gov\/cpi\/data.htm. Accessed 1 Aug 2023."},{"issue":"2","key":"594_CR42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10875-011-9631-6","volume":"32","author":"E Haddad","year":"2012","unstructured":"Haddad E, Berger M, Wang E, et al. Higher doses of subcutaneous IgG reduce resource utilization in patients with primary immunodeficiency. J Clin Immunol. 2012;32(2):281\u20139.","journal-title":"J Clin Immunol"},{"key":"594_CR43","unstructured":"Gamunex-C prescribing information. Grifols Therapeutics Inc.; 2017. https:\/\/www.gamunex-c.com\/documents\/648456\/5516391\/Gamunex-C+Prescribing+Information.pdf\/28391fe7-086f-b112-0bd4-9738108cd159?t=1688982731791."},{"key":"594_CR44","first-page":"S475","volume":"22","author":"G Krishnarajah","year":"2016","unstructured":"Krishnarajah G, Lehmann J, Ellman B, et al. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy. Am J Manag Care. 2016;22:S475\u201381.","journal-title":"Am J Manag Care"},{"key":"594_CR45","unstructured":"Cuvitru prescribing information. Baxalta US Inc.; 2018. https:\/\/www.shirecontent.com\/PI\/PDFS\/Cuvitru_USA_ENG.pdf."},{"key":"594_CR46","unstructured":"HyQvia prescribing information. Baxalta US Inc.; 2016. https:\/\/www.shirecontent.com\/PI\/PDFs\/HYQVIA_USA_ENG.pdf."},{"key":"594_CR47","unstructured":"Xembify prescribing information. Grifols Therapeutics LLC; 2020. https:\/\/www.xembify.com\/documents\/648456\/5516391\/Xembify+Prescribing+Information.pdf\/2aadd7f4-7056-226b-ea44-b7abc6a69e9d?t=1728904722502."},{"key":"594_CR48","unstructured":"Cutaquig prescribing information. Octapharma; 2021. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=12505."},{"issue":"1","key":"594_CR49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/NAN.0b013e3182798af8","volume":"36","author":"ME Younger","year":"2013","unstructured":"Younger ME, Aro L, Blouin W, Duff C, et al. Nursing guidelines for administration of immunoglobulin replacement therapy. J Infus Nurs. 2013;36(1):58\u201368.","journal-title":"J Infus Nurs"},{"issue":"4","key":"594_CR50","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1377\/hlthaff.21.4.128","volume":"21","author":"L Burns","year":"2002","unstructured":"Burns L, Pauly M. Integrated delivery networks: a detour on the road to integrated health care? Health Aff. 2002;21(4):128\u201343.","journal-title":"Health Aff"},{"issue":"8","key":"594_CR51","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2147\/PPA.S60771","volume":"2014","author":"T Espanol","year":"2014","unstructured":"Espanol T, Prevot J, Drabwell J, Sondhi S, Olding L. Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment. Patient Prefer Adhere. 2014;2014(8):621\u20139.","journal-title":"Patient Prefer Adhere"},{"issue":"4","key":"594_CR52","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/1129729818757966","volume":"19","author":"JC Barton","year":"2018","unstructured":"Barton JC, Barton JC, Bertoli LF. Implanted ports in adults with primary immunodeficiency. J Vasc Access. 2018;19(4):375\u20137.","journal-title":"J Vasc Access"},{"issue":"4","key":"594_CR53","first-page":"400","volume":"23","author":"S Kearns","year":"2017","unstructured":"Kearns S, Kristofek L, Bolgar W, Seidu L, Kile S. Clinical profile, dosing, and quality-of-life outcomes in primary immune deficiency patients treated at home with immunoglobulin G: data from the IDEaL patient registry. J Manag Care Spec Pharm. 2017;23(4):400\u20136.","journal-title":"J Manag Care Spec Pharm"},{"key":"594_CR54","unstructured":"Hizentra prescribing information. CSL Behring LLC; 2020. https:\/\/labeling.cslbehring.com\/PI\/US\/Hizentra\/EN\/Hizentra-Prescribing-Information.pdf."},{"issue":"2","key":"594_CR55","first-page":"96","volume":"18","author":"TM Windegger","year":"2020","unstructured":"Windegger TM, Nghiem S, Nguyen KH, Fung YL, Scuffham PA. Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia. Blood Transfus. 2020;18(2):96\u2013105.","journal-title":"Blood Transfus"},{"issue":"1","key":"594_CR56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1759720X11431004","volume":"4","author":"F Striesow","year":"2012","unstructured":"Striesow F, Brandt A. Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskelet Dis. 2012;4(1):3\u20139.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"594_CR57","unstructured":"Centers for Medicare & Medicaid Services (CMS). Physician fee schedule search. https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/search\/search-criteria.aspx. Accessed 18 Jan 2023."},{"key":"594_CR58","unstructured":"United States Bureau of Labor Statistics. Economic news release. Table B-3: average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector, seasonally adjusted. https:\/\/www.bls.gov\/news.release\/empsit.t19.htm. Accessed 2 Oct 2022."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00594-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00594-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00594-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:14:10Z","timestamp":1761628450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00594-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["594"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00594-y","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"10 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by CSL Behring.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr Carlton reports employment with Cencora, which received funding from CSL Behring for this analysis. Dr Mallick reports employment with CSL Behring at the time of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"We did not generate any datasets, because our work proceeded within a mathematical approach. One can obtain the relevant model inputs from the reference list.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The Excel model file is included in online supplementary materials.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Dr Mallick and Dr Carlton made substantial contributions to the conception and design of the work, the acquisition, analysis, and interpretation of data for the work; drafting the work and reviewing it critically for important intellectual content; final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}